ROVI — Laboratorios Farmaceuticos Rovi SA Balance Sheet
0.000.00%
- €3.07bn
- €3.16bn
- €763.75m
- 93
- 18
- 67
- 66
Annual balance sheet for Laboratorios Farmaceuticos Rovi SA, fiscal year end - December 31st, EUR millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 53.2 | 99 | 125 | 25.3 | 27.4 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 84.2 | 160 | 184 | 143 | 130 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Current Assets | 365 | 506 | 623 | 509 | 490 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 155 | 182 | 216 | 254 | 287 |
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 574 | 733 | 879 | 800 | 832 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 123 | 190 | 294 | 200 | 157 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Minority Interest | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 201 | 262 | 359 | 260 | 260 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Treasury Stock | |||||
| Total Equity | 374 | 471 | 520 | 539 | 572 |
| Total Liabilities & Shareholders' Equity | 574 | 733 | 879 | 800 | 832 |
| Total Common Shares Outstanding |